INSUBCONTINENT EXCLUSIVE:
Advanced Research and Development Authority (BARDA), which will be used to speed the development and testing of a handheld molecular test
that can detect the presence of the SARS-CoV-2 novel coronavirus that causes COVID-19.Cue, which broke cover in 2014 with plans for a
with a compact and connected mini lab device that can transmit results to a personalized app-based health dashboard.The startup received a
previous $30 million contract from BARDA in 2018, which was earmarked for the development and validation of an over-the-counter diagnostic
test for influenza and multiplex respiratory pathogens
have worked with the BARDA team for the past two years developing and testing a 20-minute, molecular influenza test designed for home and
funding round the same year, which was designed to help it fund the first set of FDA clinical products used to validate its first products
specific timeline for this to become available
But the fact remains that the current testing gap needs to be addressed essentially by as many solutions as can be proven effective and
